Asclera™ (polidocanol) Injection Sclerotherapy
Asclera™ was approved by the FDA on March 30 to treat uncomplicated spider veins (varicose veins less than or equal to 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremities. It has not been studied in larger varicose veins greater than 3 mm in diameter.
Once injected, it acts by damaging the cell lining of blood vessels, causing them to close and eventually disappear.
Clinical support for Asclera™ continues to grow. In the recent Phlebology study, the authors found that polidocanol demonstrated significant efficacy over other treatment options, like sodium tetradecyl sulfate (STS) 1%. In addition, patients reported better satisfaction with polidocanol than with other treatment options.
Highlights from the study include:
- The treatment success rate for polidocanol was 95% at week 12 and 95% at week 26 vs. 92% and 91% for STS, respectively; both were significantly higher than placebo (P< 0.0001).
- The majority of patients treated with polidocanol were satisfied with the treatment.
- 87% at week 12 and 84% at week 26 for patients treated with polidocanol
- 64% at week 12 and 63% at week 26 for patients treated with STS
- 14% at week 12 and 16% at week 26 for patients treated with placebo
- Treatment with polidocanol was safe and, apart